Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet’s lead program, VTX-801 for Wilson Disease, highlighted during Pfizer’s Investor Day September 15th 2020
Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020.
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation.
PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration
Happy to share the March 2020 Info Wilson newsletter from ABPWilson!
Vivet is very happy to share the March 2020
Vivet Announces Publication in Nature Communications of VTX-803 Preclinical Data
Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics
Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board.
PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare
FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies.
PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017’s
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product
Gene Therapy of Liver Diseases
In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However, as many as 30 million people may suffer from one of the more than 6,000 existing rare diseases.
